Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results

Abstract

Background/objective

To determine if treatment of exudative age-related macular degeneration (eAMD) using proton beam therapy (PBT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is safe and effective long term.

Subject/methods

Thirty eyes with newly diagnosed eAMD were enrolled in a phase I/II prospective, sham-controlled double-masked university study. Eyes were randomized 1:1:1–24 GyE, 16 GyE or sham radiation, and treated with three initial monthly intravitreal ranibizumab or bevacizumab. Subsequent anti-VEGF reinjection was based on monthly optical coherence tomography and examination for 2 years and standard of care thereafter.

Results

A total of 23 eyes completed 2-year study follow-up, of which 16 maintained monthly follow-up. Mean best-correct visual acuity (BCVA) at 2 years was similar among treatment groups (p > 0.05). The 24 GyE group required fewer anti-VEGF injections when compared with the sham group at 2 years (4.67 ± 1.9 vs 9.67 ± 3.5; p = 0.017). Extended follow-up (mean 4 years) available in 22 eyes showed persistent reduced need for anti-VEGF therapy among eyes treated with 24 GyE compared with sham radiation (2.0 ± 1.6 vs 4.84 ± 2.4 per year, p = 0.008). New and increasing geographic atrophy (GA), noted in some eyes in all treatment groups, resulted in decreased mean BCVA from baseline for the 24 GyE group on extended follow-up (p = 0.009). Possible mild radiation retinopathy noted in 15% of eyes was not visually significant.

Conclusions

Initial treatment combining PBT (24 GyE) with intravitreal anti-VEGF therapy appears to decrease the need for anti-VEGF reinjection in eyes with newly diagnosed eAMD. Radiation retinopathy risk was low and does not appear visually significant. Long-term vision was limited by GA development especially in the 24 GyE group.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Mean best-corrected visual acuity of study groups at baseline and follow-up.
Fig. 2: Mean number of anti-VEGF injections in study eye during follow-up.
Fig. 3: Change in choroidal neovascular membrane size and leakage on fluorescein angiography at baseline and at 2 years follow-up among study groups.

References

  1. 1.

    Bourne R, Jonas J, Bron A, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends, and projections. Br J Ophthalmol. 2018;102:575–85.

  2. 2.

    Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–e1234.

  3. 3.

    Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.

  4. 4.

    Ciulla TA, Danis RP, Klein SB, Malinovsky VE, Soni PS, Pratt LM, et al. Proton therapy for exudative age-related macular degeneration: a randomized sham-controlled clinical trial. Am J Ophthalmol. 2002;134:905–6.

  5. 5.

    Yonemoto LT, Slater JD, Friedrichsen EJ, Loredo LN, Ing J, Archambeau JO, et al. Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascuarlization in age-related macular degeneration: treatment techniques and preliminary results. Int J Radiat Oncol Biol Phys. 1996;36:867–71.

  6. 6.

    Flaxel CJ, Friedrichsen EJ, Smith JO, Oenick SC, Blacharski PA, Garcia CA, et al. Proton beam irradiation of subfoveal choroidal neovascularization in age-related macular degeneration. Eye (Lond). 2000;14:155–64.

  7. 7.

    Park SS, Daftari I, Phillips T, Morse LS. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irrradiation as treatment for exudative age-related macular degeneration. Retina. 2012;32:956–66.

  8. 8.

    Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology. 2013;120:317–27.

  9. 9.

    Brand C, Arnoldussen M. IRay therapy as an adjuvant therapy in newly diagnosed patients with neovascular age-related macular degeneration. Eye (Lond). 2018;32:1345–52.

  10. 10.

    Bensoussan E, Thariat J, Maschi C, Delas J, Schouver ED, Hérault J, et al. Outcomes after proton beam therapy for large choroidal melanomas in 492 patients. Am J Ophthalmol. 2016;165:78–87.

  11. 11.

    Sikuade MJ, Salvi S, Rundle PA, Errington DG, Kacperek A, Rennie IG. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye (Lond). 2015;29:1194–8.

  12. 12.

    Osmanovic S, Moisseiev E, Mishra KK, Daftari I, Moshiri A, Morse L, et al. Phase I/II randomized study of proton beam with anti–vascular endothelial growth factor for exudative age-related macular degeneration. Ophthalmol Retin. 2017;1:217–26.

  13. 13.

    Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104.

  14. 14.

    Daftari I, Mishra KK, Singh RP, Shadoan DJ, Phillips TL. An overview of the control system for dose delivery at the UCSF dedicated ocular proton beam. Int J Med Phys Clin Engg Rad Oncol. 2016;5:242–62.

  15. 15.

    Goitein M, Miller T. Planning proton therapy of the eye. Med Phys. 1983;10:275–83.

  16. 16.

    Daftari I, Mishra KK, O'Brien JM, Tsai T, Park SS, Sheen M. Fundus image fusion in EYEPLAN software: an evaluation of a novel technique for ocular melanoma radiation treatment planning. Med Phys. 2010;37:5199–207.

  17. 17.

    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58 e1.

  18. 18.

    Guyer DR, Mukai S, Eaga KM, Seddon JM, Walsh SM, Gragoudas E. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992;99:1278–95.

  19. 19.

    Zambarakji HJ, Lane AM, Ezra E, Gauthier D, Goitein M, Adams JA, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology. 2006;113:2012–9.

  20. 20.

    Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915–924 e2.

  21. 21.

    Trikha R, Morse LS, Zawadzki RJ, Werner JS, Park SS. Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration. Retina. 2011;31:1303–15.

  22. 22.

    Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci. 2006;47:4666–73.

Download references

Funding

The study was supported in part by the Strategic Opportunities Support Award, Clinical and Translational Science Institute, University of California San Francisco.

Author information

All authors met criteria for authorship by making substantial contributions to conception or design of work, acquisition, analysis, or interpretation of data, or in drafting or revising paper critically for important intellectual content. All authors approved the final version of this work.

Correspondence to Susanna S. Park.

Ethics declarations

Conflict of interest

SSP has received research support via employer from Allergan and Roche/Novartis for contracted clinical research exploring anti-VEGF drugs for treatment of retinal disorders including exudative AMD. None of the other authors have any conflict of interest to disclose.

Disclosure

Contracted research with Allergan and Roche Novartis via employer (SSP) investigating anti-VEGF therapy for retinal disorders, including macular degeneration. No other conflicting relationship exists for any of the remaining authors.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mukkamala, L.K., Mishra, K., Daftari, I. et al. Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results. Eye (2020). https://doi.org/10.1038/s41433-020-0807-2

Download citation